CGTX
Cognition Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.03
−1.90%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 129.0K | — | — | — | 235.0K |
| Gross Profit | (129.0K) | — | — | — | (235.0K) |
| Operating Expenses | |||||
| R&D Expense | 26.1M | 37.2M | 41.7M | 37.2M | 30.3M |
| SG&A Expense | 10.5M | 10.6M | 12.3M | 13.5M | 13.2M |
| General & Admin Expense | 10.5M | 10.6M | 12.3M | 13.5M | 13.2M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (61.0K) | — | — | — | (235.0K) |
| Total Operating Expenses | 36.5M | 47.8M | 54.0M | 50.7M | 43.3M |
| Cost and Expenses | 36.6M | 47.8M | 54.0M | 50.7M | 43.6M |
| Operating Income (EBIT) | (36.6M) | (47.8M) | (54.0M) | (50.7M) | (43.6M) |
| Non-Operating | |||||
| Interest Income | — | — | — | 24.8M | 22.2M |
| Interest Expense | 13.0K | 13.0K | 25.0K | 27.0K | 28.0K |
| Net Interest Income | (13.0K) | (13.0K) | (25.0K) | 24.8M | 22.2M |
| Other Non-Op Income/Expense | 19.8M | 24.3M | 20.0M | 24.9M | 22.2M |
| Non-Operating Income (excl Interest) | (19.8M) | (24.3M) | (20.0M) | (25.0M) | (22.2M) |
| EBT (Pre-Tax Income) | (16.8M) | (23.5M) | (34.0M) | (25.8M) | (21.4M) |
| Income Tax Expense | — | — | — | — | (22.2M) |
| Bottom Line | |||||
| Net Income | (16.8M) | (23.5M) | (34.0M) | (25.8M) | 757.0K |
| Earnings from Cont. Ops | (16.8M) | (23.5M) | (34.0M) | (25.8M) | 757.0K |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (16.8M) | (23.5M) | (34.0M) | (25.8M) | (21.4M) |
| Per Share | |||||
| Basic EPS | ($0.19) | ($0.32) | ($0.85) | ($0.86) | ($0.74) |
| Diluted EPS | ($0.19) | ($0.32) | ($0.85) | ($0.86) | ($0.74) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 90.6M | 72.8M | 39.7M | 30.0M | 29.0M |
| Diluted Shares Outstanding | 90.6M | 72.8M | 39.7M | 30.0M | 29.0M |
| Profitability Metrics | |||||
| EBITDA | (16.6M) | (23.2M) | (33.7M) | (25.5M) | (21.1M) |
| D&A | 190.0K | 228.0K | 266.0K | 252.0K | 235.0K |
| EBIT | (16.8M) | (23.5M) | (33.9M) | (25.8M) | (21.4M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026